Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Placido Morano

Rheumatology Brooklyn, NY Medical Doctor

NPI 1902858434 CMS profile 132062

263 7Th Ave, Brooklyn, NY 11215

Open in the dashboard

General payments

$42,834

361 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Placido Morano of Brooklyn, NY is reported in the CMS Open Payments database as having received $42,834 across 361 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $904 29
2024 General $931 27
2023 General $916 38
2022 General $676 31
2021 General $876 37
2020 General $12,600 72
2019 General $25,930 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Placido Morano
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Placido Morano were reported at $904. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Placido Morano Rheumatology median Middle half National median
2019 $25,930 $744 $153–$2,687 $163
2020 $12,600 $462 $98–$2,027 $114
2021 $876 $531 $101–$2,153 $132
2022 $676 $627 $125–$2,303 $149
2023 $916 $741 $145–$2,524 $160
2024 $931 $830 $166–$2,660 $164
2025 $904 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $19,394 84 payments
  2. Horizon Therapeutics plc $11,406 45 payments
  3. Pfizer Inc. $8,608 58 payments
  4. Amgen Inc. $748 47 payments
  5. Novartis Pharmaceuticals Corporation $722 60 payments
  6. Aurinia Pharma U.S., Inc. $595 20 payments
  7. GlaxoSmithKline, LLC. $457 20 payments
  8. AstraZeneca Pharmaceuticals LP $200 2 payments
  9. Janssen Biotech, Inc. $199 6 payments
  10. UCB, Inc. $137 4 payments
  11. Other $369 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,675 14 payments
  2. Honoraria $9,200 6 payments
  3. Food and Beverage $8,891 326 payments
  4. Travel and Lodging $3,060 14 payments
  5. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. HUMIRA $17,779 30 payments
  2. RAYOS Rayos $11,311 39 payments
  3. RAYOS Rayos $11,311 39 payments
  4. RAYOS Rayos $11,311 39 payments
  5. XELJANZ $8,591 57 payments
  6. RINVOQ $1,426 42 payments
  7. COSENTYX $705 59 payments
  8. INFLECTRA $602 22 payments
  9. LUPKYNIS $595 20 payments
  10. BENLYSTA $457 20 payments
  11. Other $2,377 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,321

Median for Rheumatology: 1,511

Drug cost

$1,320,321

Median for Rheumatology: $1,139,948

Branded share of claims

29.3%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 53 $378,257
Humira(Cf) Pen Adalimumab Brand 32 $203,265
Rinvoq Upadacitinib Brand 27 $164,239
Orencia Clickject Abatacept Brand 19 $103,306
Xeljanz Xr Tofacitinib Citrate Brand 15 $92,101
Enbrel Etanercept Brand 11 $72,202
Diclofenac Sodium Generic 86 $71,340
Xeljanz Tofacitinib Citrate Brand 12 $68,293
Prolia Denosumab Brand 24 $40,861
Rayos Prednisone Brand 11 $35,330

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$32,301

Medicare's payments for the services billed

Medicare patients

233

Average age 71

Services billed

472

192 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 43%
Ischemic heart disease 28%
Osteoporosis 26%
Chronic kidney disease 22%
Heart failure 19%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $580
$580 27 —
LUPKYNIS
  • Aurinia Pharma U.S., Inc. $171
$171 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $75
$75 — —
Enbrel
  • Amgen Inc. $66
$66 64 —
ZTLido
  • Scilex Pharmaceuticals Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

361 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record